Meet Dr. Thomas Wagner, the brains behind Orbis Health Solutions, a biotech company, and a dedicated cancer researcher. His life's mission? To find a way to treat cancer without the troubling side effects that, for some, are worse than the disease itself and may even lead to an earlier death.
According to Wagner, it's not just the diagnosis that's tragic; it's also the fear of the therapy. Traditional cancer treatments, like chemotherapy, kill both cancer and non-cancer cells, leading to side effects such as hair loss, nausea, and a weakened immune system. Witnessing patients suffer from these side effects fueled Wagner's determination to develop a cancer treatment that harnesses the power of the immune system instead of suppressing it.
His solution? A personalized vaccine, studied for decades, that uses a person's tumor cells to train the immune system to recognize and fight cancer cells. Unlike traditional therapies, this approach could potentially spare patients from debilitating side effects.
Wagner believes this innovative cancer treatment, when coupled with early detection, could be the long-awaited cure for cancer. His tumor lysate particle-only (TLPO) vaccine has shown promising results in Phase 2 clinical trials, particularly in treating advanced forms of melanoma.
Recent data revealed that nearly 95% of those given only the vaccine were still alive three years after starting treatment, with 64% remaining disease-free. Even in the most advanced cases, the vaccine-only group showed higher disease-free survival rates compared to a placebo group.
Encouraged by these findings, the Food and Drug Administration (FDA) has given the green light for a Phase 3 clinical trial. This $100 million project aims to enroll 500 people and is expected to kick off later this year.
However, financial barriers pose a challenge for smaller companies like Orbis Health Solutions. To overcome this hurdle, Wagner's team initiated a basket trial, allowing the vaccine to be tested in anyone with a solid tumor who meets specific criteria. Initial results, including the case of Catie King, diagnosed with ovarian cancer, suggest positive outcomes with minimal side effects.
Despite these promising developments, Dr. Vernon Sondak, a cutaneous oncologist, urges caution, emphasizing the need for conclusive Phase 3 clinical trials. Wagner remains hopeful, pointing to the success stories of individuals like Mary Carol Abercrombie, who defied stage 4 melanoma and has lived cancer-free for over two decades.
As the Phase 3 trial approaches, Wagner and his team hope that the data from the basket trial will attract the attention of larger pharmaceutical companies. Collaborations and additional funding mechanisms could pave the way for more extensive trials and, eventually, widespread availability of this groundbreaking cancer vaccine.
Dr. Jade A. Cobern, a board-certified pediatrician specializing in preventive medicine, and Justin Berger, a reporter with WLOS, an ABC News affiliate in Asheville, North Carolina, contributed to this insightful report.
kristin juszczyk
orbis health solutions
orbis health solutions stock
cancer vaccine